Spark Therapeutics (NASDAQ: ONCE) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Spark Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Insider and Institutional Ownership

91.0% of Spark Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.3% of Spark Therapeutics shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Spark Therapeutics and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Spark Therapeutics $20.36 million -$165.64 million -12.96
Spark Therapeutics Competitors $464.68 million $167.54 million -6.72

Spark Therapeutics’ competitors have higher revenue and earnings than Spark Therapeutics. Spark Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for Spark Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spark Therapeutics 1 1 12 0 2.79
Spark Therapeutics Competitors 1379 4469 12295 311 2.63

Spark Therapeutics currently has a consensus target price of $87.23, indicating a potential upside of 5.31%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.85%. Given Spark Therapeutics’ competitors higher probable upside, analysts plainly believe Spark Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Spark Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spark Therapeutics -962.72% -59.74% -52.08%
Spark Therapeutics Competitors -4,767.69% -355.53% -43.48%

Volatility and Risk

Spark Therapeutics has a beta of 3.38, meaning that its stock price is 238% more volatile than the S&P 500. Comparatively, Spark Therapeutics’ competitors have a beta of 6.57, meaning that their average stock price is 557% more volatile than the S&P 500.

Summary

Spark Therapeutics competitors beat Spark Therapeutics on 7 of the 12 factors compared.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.